Prescribers in the US have found “very little consensus on how we’re going to be using or deploying” biosimilars to Roche’s Lucentis (ranibizumab), and “there’s still a lot of confusion on how to incorporate biosimilars into our practice.”
That’s according to retinal and macular specialist Veeral Sheth, a professor at the University of Illinois and clinical investigator for a suite of new clinical trials currently being conducted by Roche for its next-generation eye-disease biologics: Susvimo (ranibizumab) ocular implant and Vabysmo (faricimab) VEGF
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?